Skip to main content

Changing the Odds for Kids with JMML Grant

Project Title

Risk-Adapted Treatment of Juvenile Myelomonocytic Leukemia: A Phase 2 Study

Layman’s summary

Juvenile myelomonocytic leukemia (JMML) is an aggressive blood cancer that occurs in young children. Only half of patients are cured with standard treatment. With prior support from Cannonball Kids’ cancer, Dr. Stieglitz was able to show that a combination of two new treatments were particularly effective in JMML and was therefore able to open a nation-wide clinical trial testing the medications. Now that they’ve shown that these medications are safe, the phase 2 portion of the trial will be treating up to 50 more patients. This grant was co-funded by Trial Blazers for Kids.

Elliot Stieglitz

This Project By The Numbers

  • Years Active
    3
  • Amount Awarded
    $200,000
  • Institution
    University of California, San Francisco

Additional CKc Funded Research